VistaGen Therapeutics Inc (VTGN)


Stock Price Forecast

March 18, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading VistaGen Therapeutics Inc chart...

About the Company

we have developed a versatile stem cell technology platform based on the controlled differentiation of human pluripotent stem cells into mature, non-transformed, human cells which can be used to create novel bioassay systems for predictive toxicology, drug metabolism screening, drug discovery, drug rescue and cell therapy. we believe our stem cell technology platform, human clinical trials in a test tube™, can provide clinically relevant predictions of potential toxicity and metabolism issues of promising new drug candidates long before they are ever tested in humans.

Exchange

NASDAQ

Website

vistagen.com

$0M

Total Revenue

33

Employees

$839M

Market Capitalization

-0.14

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $VTGN News

Why VistaGen Therapeutics Is A Buy: Fasedienol Potential For Anxiety Treatments

2d ago, source: Seeking Alpha

VistaGen Therapeutics, Inc. (NASDAQ:VTGN), established in 1998 and headquartered in South San Francisco, California, is ...

VistaGen Therapeutics, Inc.

2mon ago, source: CNN

VistaGen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central ...

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2024 Earnings Call Transcript

1mon ago, source: Insider Monkey

VistaGen Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.22, expectations were $-0.31. VTGN isn’t one of the 30 most popular stocks among hedge funds at the end of the third ...

Investornewsbreaks - Vistagen Therapeutics Inc.'S (NASDAQ: VTGN) Announces Participation At Upcoming Stifel 2024 Virtual CNS Days

7d ago, source:

Vistagen Therapeutics (NASDAQ: VTGN) , a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affec ...

Vistagen Therapeutics Inc VTGN

5d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Vistagen Therapeutics Inc.

22d ago, source: TheStreet.com

Below is a summary of the major fundamental and technical factors we consider when determining our overall recommendation of VTGN shares. It is provided in order to give you a deeper understanding ...

VistaGen Therapeutics Inc.

19d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Vistagen Therapeutics Inc VTGN

20d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...